ew report result beat consensu estim top-lin behind robust tavr
growth miss slightli adj ep due one-tim cost associ chang
cardioband manufactur acceler spend drive tavr therapi awar
tavr growth acceler underli driven fda low-risk
indic august improv awar benefit new ncd nation
coverag determin consequ ew rais overal tavr growth
outlook around high-end previou rang increas total sale
adj ep guidanc nonetheless still see room potenti upsid compani
guid behind strength tavr remain posit bias ew share rais
pt reiter ow rate
top-lin driven tavr close ew report result
total sale underli y/i street model
top-lin beat driven tavr growth underli led
busi grew around level procedur standpoint adjust
gross margin y/i impact one-tim cost associ
move cardioband product ireland israel expens relat eu devic
regul adj oper margin y/i came forecast due
lower gross margin higher sg spend model bottom line
adj ep consensu estim due
gross margin strateg choic acceler spend drive tavr therapi
guidanc rais call ew lift bottom report
sale guidanc compani also updat underli growth
outlook around top-end previou rang manag note growth
expect slow throughout due y/i comp dynam ew rais
adj ep report prior revis
outlook larg driven compani updat tavr guidanc includ
underli growth around top-end previou rang report
sale prior report sale guidanc ew
busi unchang compani report sale adj ep guidanc
respect
competit price pressur product delay advers clinic data litig
ew develop manufactur sell product treat structur heart diseas
provid critic care monitor market leader tavr valv
adj ep
debt total capit
piper sandler seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
tavr global tavr sale underli easili eclips street expect
ew tavr growth strong across geographi led procedur
growth compani estim ou tavr market grew high-teen procedur
basi ew post compar growth robust tavr growth broad-bas
across small larger center driven low-risk increas therapi awar
updat tavr ncd help growth number tavr
tmtt ew tmtt transcathet mitral transcathet tricuspid sale miss street
expect latter didnt appear reflect compani commentari
decemb analyst day manag note compani continu launch pascal
disciplin approach premium price strategi ew reiter previou guidanc
remain optimist long-term commerci prospect tmtt portfolio
pipelin front ew said remain track mileston discuss analyst
day earli decemb
surgic structur heart critic surgic structur heart ssh sale
littl short consensu critic cc sale
manag re-affirmed previou sale guidanc ssh cc call
ssh shortfal quarter primarili driven acceler tavr growth
stock encourag strong finish year tavr
growth come lofti street expect although ew increas top-lin growth
adj ep guid still see room potenti upsid larg driven outsiz tavr growth
remain posit bias share reiter ow rate rais price target
pt base adj ep estim vs prior
reflect continu posit outlook share
page
page
y/yactual-estimateadjust interest expens incom incom analysi gross gener develop oper growthnmnmnmnmsurg structur compani report piper sandler estim edward lifesci corpor ew
million
sale
revenu report
current disclosur inform compani locat http //www pipersandl com/researchdisclosur
